Showing 861-870 of 2740 results for "".
Advances in PsO: Targeting IL-23
https://practicaldermatology.com/conferences/aad-summer-2021/advances-in-pso-targeting-il-23/19974/George Han, MD, PhD reviews the latest data available on IL-23 inhibitors for the treatment of psoriasis. He discusses the specific benefits of guselkumab, tildrakizumab, and risankizumab and shares insights about how they fit into the overall psoriasis treatment arsenal.COVID-19 Impact: iPledge and Isotretinoin Prescribing
https://practicaldermatology.com/topics/acne-rosacea/covid-19-impact-ipledge-and-isotretinoin-prescribing/19763/For patients on isotretinoin, complying with the iPledge program while treating patients virtually can be challenging. Joshua Zeichner, MD discusses new FDA guidance that allows female patients to take OTC pregnancy tests in order to continue treatment. He also discusses when patients do and do notAdvances in Tattoo Removal and More
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/advances-in-tattoo-removal-and-more/19756/Eric Bernstein, MD shares insights on the benefits of picosecond domain lasers for everything from rejuvenation to tattoo removal. He discusses his recent experience with the 730nm handpiece and its efficacy on multiple ink colors and all skin types. In addition, he talks about other new technologieLight & Bright: A new treatment to illuminate your practice
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/light-bright-a-new-treatment-to-illuminate-your-practice/19746/Join Matthew Mahlberg, MD as he introduces the new Light & Bright treatment. Using the patented Ellipse IPL and Frax 1550 technologies on the Nordlys system, the Light & Bright treatment reduces pigmentation & redness and improves textural irregularities. Hear the results of a clinical sThe Role of Microneedling in Practice
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-role-of-microneedling-in-practice/18627/Microneedling is gaining in popularity. Amy Forman Taub, MD discusses how she's using microneedling in combination with other treatments like PDT and RF to enhance efficacy and for faster results. She says the number one reason she uses microneedling is for scars. She also cautions on when not to usTargeting Senescent Cells
https://practicaldermatology.com/series/c-suite-chats/targeting-senescent-cells/35960/Rubedo Life Science CEO Frederick Beddingfield III, MD, PhD, FAAD, FACMS, talks about the importance of addressing aging and senescence, and his company's investigational drug that targets pathological senescent cells and surrounding tissues that drive inflammaging and chronic degenerative diseasesLaser Innovations on the Horizon
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/laser-innovations-on-the-horizon/18534/Jill Waibel, MD discusses advances in lasers and what's on the horizon. She shares insights on a new and improved pulsed dye laser plus RF; fractional applications being investigated for scars, vitiligo, wrinkles, and more; plus devices for vaginal rejuvenation.PsO Many Options: The Expanded Psoriasis Landscape
https://practicaldermatology.com/topics/psoriasis/pso-many-options-the-expanded-psoriasis-landscape/18749/By Jeffrey Weinberg, MD and Seemal R. Desai, MDWith many new therapies coming out in oral, topical, and biologic forms, there are fewer unmet needs in psoriasis management now than ever before. Dr. Weinberg navigates the therapeutic landscape.Atopic Dermatitis: Understanding the Impact
https://practicaldermatology.com/topics/atopic-dermatitis/atopic-dermatitis-understanding-the-impact/19667/For most AD patients, eczema is a bumpy ride. Even mild cases of atopic dermatitis can have a significant effect on people—and these effects range from quality of life impact to treatment costs. Peter Lio, MD describes his approach to a long-term eczema management plan.FDA Approves Roflumilast for Seborrheic Dermatitis in Young Patients
https://practicaldermatology.com/topics/other-dermatitis/fda-approves-roflumilast-for-seborrheic-dermatitis-in-young-patients/20230/Patrick Burnett, MD, PhD, chief medical officer of Arcutis Biotherapeutics, talks with Practical Dermatology® about the first new treatment for seborrheic dermatitis in more than 20 years, their newly approved ZORYVE (roflumilast)Topical Foam, 0.3% for use in patients aged 9 years or older.